Snyder Capital Management L P lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 156,879 shares of the medical research company's stock after selling 3,173 shares during the quarter. Snyder Capital Management L P owned 0.09% of IQVIA worth $30,828,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of IQV. Integrated Wealth Concepts LLC lifted its holdings in IQVIA by 25.8% during the 4th quarter. Integrated Wealth Concepts LLC now owns 2,761 shares of the medical research company's stock worth $543,000 after buying an additional 566 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in IQVIA by 63.7% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 38,860 shares of the medical research company's stock worth $7,636,000 after buying an additional 15,127 shares during the last quarter. Syon Capital LLC lifted its holdings in IQVIA by 34.0% during the 4th quarter. Syon Capital LLC now owns 1,138 shares of the medical research company's stock worth $224,000 after buying an additional 289 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in IQVIA by 27.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,520 shares of the medical research company's stock worth $496,000 after buying an additional 544 shares during the last quarter. Finally, Hsbc Holdings PLC lifted its holdings in IQVIA by 5.1% during the 4th quarter. Hsbc Holdings PLC now owns 416,381 shares of the medical research company's stock worth $81,856,000 after buying an additional 20,323 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.
Wall Street Analyst Weigh In
Several analysts recently issued reports on IQV shares. Stifel Nicolaus cut their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. UBS Group cut their price target on IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a report on Friday, February 7th. JPMorgan Chase & Co. cut their price target on IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th. HSBC downgraded IQVIA from a "buy" rating to a "hold" rating and cut their price target for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Finally, Morgan Stanley raised their price target on IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $237.62.
Read Our Latest Stock Analysis on IQV
IQVIA Stock Down 0.7 %
Shares of NYSE IQV traded down $1.10 during mid-day trading on Wednesday, reaching $152.35. The company had a trading volume of 737,067 shares, compared to its average volume of 1,423,121. The stock has a fifty day moving average of $169.86 and a two-hundred day moving average of $192.72. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market capitalization of $26.86 billion, a price-to-earnings ratio of 20.31, a PEG ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
